NSI-189 vs Vinpocetine

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners

Mechanism

Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.

Standard Dosing

5-20 mg 2-3 times daily (15-60 mg/day total)

Timing

With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).

Cycle Duration

Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.

Side Effects

• Flushing
• GI distress
• Headache
• Dizziness
• Transient hypotension
• Sleep disturbance

Contraindications

• Severe hepatic impairment
• Pregnancy and lactation (FDA issued warning in 2019)
• Severe cardiac arrhythmias
• Recent hemorrhagic stroke

Best Stacking Partners